Oscar Health, Inc. (NYSE:OSCR) Receives $19.22 Consensus Price Target from Analysts

Oscar Health, Inc. (NYSE:OSCR) has earned an average recommendation of “Hold” from the twelve ratings firms that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $19.2222.

A number of analysts have recently issued reports on OSCR shares. Raymond James Financial raised Oscar Health from a “market perform” rating to an “outperform” rating and set a $18.00 price target on the stock in a research note on Thursday, February 12th. Robert W. Baird lifted their price target on Oscar Health from $15.00 to $19.00 and gave the stock a “neutral” rating in a research note on Thursday, May 7th. UBS Group lifted their target price on Oscar Health from $15.00 to $20.00 and gave the company a “neutral” rating in a research report on Thursday, May 7th. Barclays lifted their target price on Oscar Health from $21.00 to $30.00 and gave the company an “equal weight” rating in a research report on Tuesday, May 26th. Finally, Wall Street Zen upgraded Oscar Health from a “hold” rating to a “strong-buy” rating in a research report on Saturday, May 9th.

Oscar Health Stock Performance

Shares of NYSE:OSCR opened at $22.24 on Wednesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.11 and a quick ratio of 1.11. The business’s 50 day moving average price is $17.38 and its 200-day moving average price is $15.78. The firm has a market capitalization of $6.71 billion, a PE ratio of -37.70, a P/E/G ratio of 1.55 and a beta of 2.37. Oscar Health has a 1 year low of $10.69 and a 1 year high of $25.58.

Oscar Health (NYSE:OSCR) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $2.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.11 by $0.96. The firm had revenue of $4.65 billion for the quarter, compared to analyst estimates of $4.90 billion. Oscar Health had a negative return on equity of 3.26% and a negative net margin of 0.30%.The business’s revenue was up 52.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.92 earnings per share. As a group, equities research analysts expect that Oscar Health will post 0.47 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Mark T. Bertolini acquired 1,000,000 shares of the company’s stock in a transaction dated Monday, April 6th. The stock was acquired at an average cost of $11.92 per share, with a total value of $11,920,000.00. Following the completion of the purchase, the chief executive officer owned 10,196,876 shares of the company’s stock, valued at $121,546,761.92. This represents a 10.87% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Richard Scott Blackley sold 100,000 shares of Oscar Health stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $23.16, for a total value of $2,316,000.00. Following the completion of the sale, the chief financial officer directly owned 1,216,660 shares of the company’s stock, valued at $28,177,845.60. The trade was a 7.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 25.11% of the company’s stock.

Institutional Investors Weigh In On Oscar Health

Institutional investors have recently modified their holdings of the company. BIT Capital GmbH raised its position in Oscar Health by 545.0% in the 4th quarter. BIT Capital GmbH now owns 6,186,267 shares of the company’s stock valued at $88,897,000 after purchasing an additional 5,227,152 shares in the last quarter. American Century Companies Inc. raised its position in Oscar Health by 89.0% in the 3rd quarter. American Century Companies Inc. now owns 5,298,340 shares of the company’s stock valued at $100,298,000 after purchasing an additional 2,495,691 shares in the last quarter. Farallon Capital Management LLC raised its position in Oscar Health by 146.5% in the 3rd quarter. Farallon Capital Management LLC now owns 3,639,000 shares of the company’s stock valued at $68,886,000 after purchasing an additional 2,163,000 shares in the last quarter. Morgan Stanley raised its position in Oscar Health by 42.8% in the 4th quarter. Morgan Stanley now owns 6,814,046 shares of the company’s stock valued at $97,918,000 after purchasing an additional 2,043,758 shares in the last quarter. Finally, Bank of America Corp DE raised its position in Oscar Health by 205.1% in the 1st quarter. Bank of America Corp DE now owns 2,860,310 shares of the company’s stock valued at $32,808,000 after purchasing an additional 1,922,732 shares in the last quarter. 75.70% of the stock is owned by institutional investors and hedge funds.

Oscar Health Company Profile

Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.

The company’s primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.